All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
During the Pan Pacific Lymphoma Congress, the Lymphoma Hub spoke with Neha Mehta-Shah, Washington University School of Medicine, St. Louis, US. We asked, What is on the horizon for treating peripheral T-cell lymphoma?
What is on the horizon for treating peripheral T-cell lymphoma?
Mehta-Shah begins by outlining the drug classes of some emerging treatments for peripheral T-cell lymphoma, including JAK and STAT inhibitors. Mehta-Shah also touches on the PRIMO study, investigating duvelisib and other PI3 kinase inhibitors. Finally, Mehta-Shah highlights new studies investigating allogeneic CAR T-cells and discusses the VALENTINE study.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox